Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results
U.S. IND filed for THB335 with anticipated clinical trial start during 2Q’24 Strong financial position with cash and cash equivalents...
Clinical Trial
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
Company generated approximately $2.8M of non-dilutive funding to extend cash runwayWESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech...
Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update
BETHESDA, Md., March 26, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...
Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research
NEWPORT BEACH, Calif., March 26, 2024 (GLOBE NEWSWIRE) -- Healis Therapeutics is pleased to announce that it has entered a...
FDA Approves Medexus’s Supplemental Biologics License Application for IXINITY(R) to Treat Hemophilia B in Pediatric Patients
Expanded indication includes patients under 12 years of age, based on Phase 3/4 data demonstrating safety and efficacy in previously...
Translational Vision Science and Technology Journal Publishes RadiusXR’s NOVA Clinical Trial, Demonstrating Industry-Leading Accuracy and Innovation in Visual Field Testing for Virtual Reality Perimetry
PLEASANTON, Calif.--(BUSINESS WIRE)--#Ophthalmology--RadiusXR, the trailblazer in Digital Health, announces the publication of its groundbreaking NOVA Clinical Trial in Translational Vision...
ProteinQure Announces A Breakthrough Therapeutic with Remarkable Efficacy in Heterogenous Patient-Derived Xenograft Models of Triple-Negative Breast Cancer to be presented at AACR
TORONTO, ON / ACCESSWIRE / March 25, 2024 / ProteinQure, the leading startup in the computational design of peptide drugs,...
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
Non-dilutive funding strengthens balance sheet and extends current operating runway LAWRENCEVILLE, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- IMUNON, Inc....
Indaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual Meeting
Data demonstrates that Company’s Decoy platform successfully induces or activates multiple immune cell types involved in anti-tumor responses New data shows...
NeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
NeuroStar is the first and only TMS therapy cleared as an adjunct treatment for patients ages 15 and olderMALVERN, Pa.,...
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis...
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company...
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
Key Highlights: Cholesterol Efflux MediatorTM VAR 200 on target to begin Phase 2a clinical trial in patients with diabetic kidney...
Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
SOUTH SAN FRANCISCO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations at the...
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
HANOVER, MD, March 25, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical...
Linkage of Cancer and Lupus in Gliomas Patients
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of...
TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters
New program extends leadership of Y90 for treatment planningCHICAGO, March 25, 2024 (GLOBE NEWSWIRE) -- TeleDaaS™, PLLC, the leading dosimetry-as-a-service...
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist
-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight...
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
Matinas' Positivein vivo Safety Data with its Oral LNC-Docetaxel Formulation Oral LNC-Docetaxel is significantly less toxic than IV-Docetaxel Daily oral...
NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress
NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or...